IPSEN (IPN.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:IPN - FR0010259150 - Common Stock
IPN.PA Key Statistics, Chart & Performance
The current stock price of IPN.PA is 119 EUR. In the past month the price decreased by -4.57%. In the past year, price increased by 5.03%.
IPN.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.93 | 201.70B | ||
| 1SAN.MI | SANOFI | 10.93 | 201.70B | ||
| SAN.PA | SANOFI | 10.88 | 200.93B | ||
| MRK.DE | MERCK KGAA | 14.37 | 53.30B | ||
| UCB.BR | UCB SA | 37.17 | 46.41B | ||
| UNC.DE | UCB SA | 36.84 | 46.00B | ||
| BAYN.DE | BAYER AG-REG | 6.93 | 36.36B | ||
| 1BAYN.MI | BAYER AG-REG | 6.87 | 36.05B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.64 | 10.15B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 100.48 | 9.30B | ||
| VIRP.PA | VIRBAC SA | 20.62 | 3.00B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 18.3 | 2.12B |
Related stock screener links
About IPN.PA
Company Profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,358 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Company Info
IPSEN
65 Quai Georges Gorse
Boulogne-Billancourt ILE-DE-FRANCE FR
Employees: 5358
Phone: 33158335000
IPSEN / IPN.PA FAQ
What does IPN do?
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,358 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
What is the stock price of IPSEN today?
The current stock price of IPN.PA is 119 EUR.
What is the dividend status of IPSEN?
IPSEN (IPN.PA) has a dividend yield of 1.17%. The yearly dividend amount is currently 1.2.
How is the ChartMill rating for IPSEN?
IPN.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What sector and industry does IPSEN belong to?
IPSEN (IPN.PA) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does IPSEN have?
IPSEN (IPN.PA) currently has 5358 employees.
What is the market capitalization of IPN stock?
IPSEN (IPN.PA) has a market capitalization of 9.97B EUR. This makes IPN.PA a Mid Cap stock.
IPN.PA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IPN.PA. When comparing the yearly performance of all stocks, IPN.PA turns out to be only a medium performer in the overall market: it outperformed 52.79% of all stocks.
IPN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA. IPN.PA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
IPN.PA Financial Highlights
Over the last trailing twelve months IPN.PA reported a non-GAAP Earnings per Share(EPS) of 10.27. The EPS increased by 12.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.91% | ||
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| Debt/Equity | 0.2 |
IPN.PA Forecast & Estimates
18 analysts have analysed IPN.PA and the average price target is 131.89 EUR. This implies a price increase of 10.84% is expected in the next year compared to the current price of 119.
For the next year, analysts expect an EPS growth of 10.08% and a revenue growth 8.8% for IPN.PA